Physician profile
Henry Rojas
NPI 1700970670
$8,503.57
in general payments reported to CMS, 2019-2025
36 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $858 · 2021: $1,252 · 2022: $991 · 2023: $1,380 · 2024: $1,377 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,819.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $955.72 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $883.73 | 2021-2024 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $789.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $439.09 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Arbor Pharmaceuticals, INC. | $392.42 | 2019-2022 | |
| Pfizer INC. | $317.55 | 2019-2025 | |
| Allergan, INC. | $295.78 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $262.79 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $243.07 | 2019-2021 | |
| Amarin Pharma, INC. | $230.16 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.07 | 2020-2023 | Stiolto Respimat |
| Exact Sciences Corporation | $208.89 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $168.18 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.88 | 2020-2023 | Trintellix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $94.14 | 2019-2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $92.91 | 2021 | |
| Merck Sharp & Dohme LLC | $85.95 | 2019-2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $85.59 | 2022-2024 | |
| Acerus Pharmaceuticals Corporation | $80.08 | 2021-2022 | |
| Mylan Specialty L.P. | $68.55 | 2019 | |
| Idorsia Pharmaceuticals US INC | $64.60 | 2022-2023 | Quviviq |
| Lundbeck LLC | $61.20 | 2025 | Rexulti |
| Astellas Pharma US INC | $60.31 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $56.13 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $55.85 | 2019-2021 | |
| Axsome Therapeutics, INC. | $44.98 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.12 | 2021 | |
| Halozyme INC | $41.44 | 2023 | |
| Sanofi-Aventis U.S. LLC | $39.64 | 2021 | |
| Horizon Therapeutics Plc | $34.49 | 2021 | |
| Azurity Pharmaceuticals, INC. | $31.84 | 2023 | Edarbi, Edarbyclor |
| Abbott Laboratories | $30.51 | 2019 | |
| Clarus Therapeutics INC. | $18.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.73 | 2021 | |
| Boston Scientific Corporation | $16.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.